Ribo Newsroom
-
Ribo raised 470 million yuan in its Series C2 financingSuzhou Ribo Life Science Co., Ltd. announced today that 470 million yuan was raised during its Series C2 financing. In this round of financing, the lead investors included China Venture Capital Fund Corporation Ltd., CICC Qide Fund, and GL Ventures, and the co-investors included renowned investment institutes such as Hengxu Capital, Everest VC, SinApril 3, 2020 -
Ribo raised 200 million yuan in its Series C1 financingOn December 5, 2019, Suzhou Ribo Life Science Co. Ltd., announced the successful completion of Series C1 financing worth RMB 203 million.December 5, 2019 -
Ribo completed the enrollment of the first patient into the Chinese phase II clinical trial on ASOISIS449884 InjectionSuzhou Ribo Life Science Co., Ltd. today announced that its phase II clinical trial of ISIS449884 Injection, an ASO for the treatment of type 2 diabetes, had completed the enrollment of the first patient and the subject was successfully administered the first dose of study drug.October 9, 2019 -
Ribo was selected as one of 2019 "Most Innovative Pharmaceutical Companies in Asia" by Clarivate AnalyticsSeptember 3, 2019 -
Ribo's clinical application for new oligonucleotide therapeutics in the treatment of type 2 diabetes got approvedRecently, the Center for Drug Evaluation, National Medical Products Administration completed the technical review on the application for a clinical trial of a new oligonucleotide therapeutics for the treatment of type 2 diabetes submitted by Suzhou Ribo Life Science Co., Ltd., and issued the Notice for Clinical Trial.January 2, 2019 -
The clinical application of Suzhou Ribo for new drug for treatment of type 2 diabetes got accepted by CDERecently, Center for Drug Evaluation, National Medical Products Administration officially accepted the clinical trial application of imported drug ISIS449884 Injection submitted by Suzhou Ribo Life Science Co. Ltd.,. This product belongs to Class 1 innovative drug not marketed in China or abroad, and the proposed indication is type 2 diabetes.July 12, 2018